Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03919994 · ClinicalTrials.gov registry record
Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)
A clinical trial, sponsored by Alkermes.
- Completed
- Registry status
- 338
- Enrollment target
NCT03919994 is a clinical trial that has completed, run by Alkermes. The registered enrollment target is 338 participants.
The verdict
NCT03919994 has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- 338 participants
- Enrollment target
Study Summary
The objectives of this study are to describe characteristics, treatment patterns, and outcomes of patients with schizophrenia newly initiated on 1 of 4 FDA-approved atypical Long Acting Injectable (LAI) antipsychotics (ABILIFY MAINTENA®, ARISTADA®, INVEGA SUSTENNA® or RISPERDAL CONSTA®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2019-03-28 |
| Est. Completion | 2023-01-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03919994
The ClinicalTrials.gov registry entry for NCT03919994 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 338 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03919994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03919994 about?
NCT03919994 is a clinical study titled "Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)". The objectives of this study are to describe characteristics, treatment patterns, and outcomes of patients with schizophrenia newly initiated on 1 of 4 FDA-approved atypical Long Acting Injectable (LAI) antipsychotics (ABILIFY MAINTENA®, ARISTADA®, INVEGA SUSTENNA® or RISPERDAL CONSTA®)
What is the current status of trial NCT03919994?
This trial is currently completed. The enrollment target is 338 participants. The study started on 2019-03-28. Estimated completion is 2023-01-04.
Who is sponsoring clinical trial NCT03919994?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.